Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07736963
Recruiting Not applicable

Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy

NCT07736963 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-09-03

Condition(s) studied

GLP-1

Investigational drug(s) / intervention(s)

GLP-1 not stop for 1 weekGLP-1 stop for 1 week

GLP-1 not stop for 1 week: GLP-1 not stop for 1 week

GLP-1 stop for 1 week: GLP-1 stop for 1 week

Study summary

This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Inclusion Criteria for non GLP-1 user: * Individuals who are scheduled to undergo total colonoscopy for any reasons * Age between 18 to 70 years. * ECOG Performance status is 0 or 1. * Written consent to participate in the study has been obtained. * Outpatient department patient * Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility. Exclusion Criteria: * • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible). * Family history of hereditary colorectal cancer syndromes. * Current or prior diagnosis of inflammatory bowel disease. * Known colorectal polyposis syndromes. * Any other condition deemed inappropriate for study participation at the discretion of the treating physician. * Body mass index (BMI) \> 40 kg/m². * Diagnosis of liver cirrhosis. * Diagnosis of Parkinson's disease. * Diagnosis of dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
FJUH New Taipei Taiwan Recruiting

More Fu Jen Catholic University Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07736963 on ClinicalTrials.gov ↗ ← All trials in Taiwan